AUTHOR=Catarinella Davide , Williford Sarah , Rusconi Francesca , Caldara Rossana , Piemonti Lorenzo 
  
TITLE=Simultaneous Pancreas–Kidney Versus Kidney Transplant Alone: Real-World Outcomes in a Propensity-Matched Global Cohort
  
JOURNAL=Transplant International
  
VOLUME=Volume 38 - 2025
  
YEAR=2025
  
URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15709
  
DOI=10.3389/ti.2025.15709
  
ISSN=1432-2277
  
ABSTRACT=The true comparative effectiveness of simultaneous pancreas–kidney transplantation (SPKT) versus kidney transplantation alone (KTA) in patients with diabetes and end-stage renal disease remains incompletely defined. Using the TriNetX Global Collaborative Network (2010–2024), we identified 3,679 SPKT and 27,062 KTA recipients aged 18–59 years. In unmatched comparisons, SPKT recipients showed lower mortality, fewer cardiovascular events, and improved kidney graft survival relative to KTA recipients, but also higher early rejection, infection, and readmission rates. After 1:1 propensity score matching, the cohorts were well balanced across all measured covariates, and long-term estimates for survival (HR 1.00, 95% CI 0.90–1.10), kidney graft failure (HR 0.99, 95% CI 0.94–1.04), and cardiovascular events (HR 0.99, 95% CI 0.94–1.05) no longer differed over 10 years. In contrast, SPKT recipients maintained significantly lower HbA1c levels throughout follow-up (mean 6.2% vs. 6.6% at 5 years; p < 0.001), reflecting sustained physiologic glycaemic control and a high probability of insulin independence. Sensitivity analyses restricted to type 1 diabetes and non-obese recipients yielded consistent results. After accounting for measured differences between recipients, we did not detect a long-term survival advantage of SPKT over KTA, whereas durable metabolic benefits persisted. Because key donor and immunologic characteristics were not available, a modest intrinsic survival benefit cannot be excluded. These findings highlight the major role of patient selection and support individualised use of SPKT for metabolic indications and quality-of-life improvement rather than survival gain alone.